FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Commentary|Videos|March 26, 2024
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
Author(s)Grace Halsey
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
Advertisement
Steven Nissen, MD, spoke with Patient Care about the findings from the landmark CLEAR Outcomes trial that support the new labeling for bempedoic acid as the only non-statin drug indicated to reduce cardiovascular risk. Nissen is Chief Academic Officer, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH and the primary investigator for the bempedoic acid and bempedoic acid plus ezetimibe clinical trial program.
This is an excerpt from a longer interview; additional content will be available shortly.
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5